37. 一流誌での報告事例
コルヒチンによる心膜炎の再発予防
方法の節方法の節
– 統計解析の項
» We needed 120 patients, 60 in each treatment group, to
detect a 50% relative reduction in the risk for recurrence
(50% in the placebo group vs. 25% in the colchicine group)
with a power of 80%, using a 2-sided α value of 0.05. Thep , g
estimated 50.0% rate of recurrent pericarditis in the
placebo group was based on the preliminary findings of the
CORE trial (4) Analyses were performed by intention toCORE trial (4). Analyses were performed by intention to
treat.
37Imazio et al: Ann Intern Med 155: 409-414, 2011
38. 一流誌での報告事例
コルヒチンによる心膜炎の再発予防
結果の節結果の節
» At 18 months, the recurrence rate was 24% in the
colchicine group and 55% in the placebo group (absolute
i k d ti 0 31 [95% CI 0 13 t 0 46] l ti i krisk reduction, 0.31 [95% CI, 0.13 to 0.46]; relative risk
reduction, 0.56 [CI, 0.27 to 0.73]; number needed to treat,
3 [CI, 2 to 7]).
38Imazio et al: Ann Intern Med 155: 409-414, 2011
40. 一流誌での報告事例
コルヒチンによる心膜炎の再発予防
考察の節考察の節
– 結論
» In summary, adding colchicine to empirical anti-
inflammatory therapy seems to be an inexpensive and safe
means to hasten symptom resolution, improve remission
rates by 1 week, and reduce recurrence after an initialy ,
recurrence of pericarditis.
40Imazio et al: Ann Intern Med 155: 409-414, 2011
41. 一流誌での報告事例
コルヒチンによる心膜炎の再発予防
要旨の節要旨の節
– 結果の項
» At 18 months, the recurrence rate was 24% in the
colchicine group and 55% in the placebo group (absolute
risk reduction, 0.31 [95% CI, 0.13 to 0.46]; relative risk
reduction, 0.56 [CI, 0.27 to 0.73]; number needed to treat,, [ , ]; ,
3 [CI, 2 to 7]).
– 結論の項
C l hi i i f d ff ti f d ti f» Colchicine is safe and effective for secondary prevention of
recurrent pericarditis.
41Imazio et al: Ann Intern Med 155: 409-414, 2011